


Lorlatinib found to be safe and effective for patients with ALK-driven relapsed/refractory high-risk neuroblastoma

April 3 2023



Efficacy of lorlatinib in patients with MIBG avid relapsed or refractory ALK-driven neuroblastoma. Shown are waterfall plots summarizing the best percentage change from baseline in MIBG avidity (change in overall MIBG Curie score (soft tissue and bone avid lesions) from baseline MIBG Curie score). Bar color represents BOR according to NANT response criteria 2.0. Cohort A1: patients ≥12 months to

Citation: Lorlatinib found to be safe and effective for patients with ALK-driven relapsed/refractory high-risk neuroblastoma (2023, April 3) retrieved 28 December 2023 from https://medicalxpress.com/news/2023-04-lorlatinib-safe-effective-patients-alk-driven.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.